INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

A leading U.S. securities‑law firm, Faruqi & Faruqi, LLP, announced on December 4, 2025 that it is investigating potential class‑action claims against MoonLake Immunotherapeutics (NASDAQ: MLTX) and urges investors who purchased MoonLake securities between March 10, 2024 and September 29, 2025 to contact the firm — especially those seeking to serve as lead plaintiff. The complaint alleges that MoonLake and its executives made false and/or misleading statements and failed to disclose material facts regarding the difference between MoonLake’s Nanobody‑based drug candidate (code‑named SLK / Sonelokimab) and conventional monoclonal‑antibody treatments — including misleading claims about SLK’s molecular targets (IL‑17A and IL‑17F), supposed superior tissue penetration, and asserted clinical benefits over existing drugs such as BIMZELX. On September 28, 2025, MoonLake released the 16‑week data from its Phase 3 “VELA” program, showing that SLK failed to demonstrate competitive efficacy versus BIMZELX. As a result, the company’s share price collapsed by USD 55.75 per share — a drop of 89.9% — closing at $6.24 on September 29. Faruqi & Faruqi highlighted that the court-appointed lead plaintiff will represent the broader class of investors who lost money, though any eligible shareholder may choose to apply. The firm also welcomed information from whistleblowers, former employees, or other stakeholders. If you believe you may qualify and want to explore your legal rights, you can contact Faruqi & Faruqi partner James (Josh) Wilson at 877‑247‑4292 or 212‑983‑9330 (Ext. 1310). #MoonLake #SecuritiesFraud #ClassAction #InvestorAlert #SlimScan #GrowthStocks #CANSLIM